Market Place
Sourcing Support
Incyte Appoints Suketu (Suky) Upadhyay As Chief Financial Officer
28 Apr 2026 //
PHARMIWEB
Incyte to Report First Quarter Financial Results
09 Apr 2026 //
BUSINESSWIRE
Adagene & Incyte to Trial Muzastotug + TGFßR2xPD-1 in CRC
02 Apr 2026 //
GLOBENEWSWIRE
Incyte Povorcitinib Shows 54-Week Data In HS At AAD
28 Mar 2026 //
BUSINESSWIRE
Incyte To Present At Upcoming Investor Conferences
17 Feb 2026 //
BUSINESSWIRE
Incyte Unveils 2025 Q4 And Full-Year Financials
10 Feb 2026 //
BUSINESSWIRE
Incyte Reports Opzelura Sales Up 33% In 2025, Plots `26 Growth
10 Feb 2026 //
FIERCE PHARMA
Incyte To Report 2025 Q4 And Year-End Financial Results
27 Jan 2026 //
BUSINESSWIRE
Incyte To Present At Upcoming Investor Conference
18 Dec 2025 //
BUSINESSWIRE
Incyte Announces Change To Its Board Of Directors
12 Dec 2025 //
BUSINESSWIRE
Incyte Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
03 Dec 2025 //
BUSINESSWIRE
Incyte Taps Winnie Harlow To Model Vitiligo Awareness
02 Dec 2025 //
FIERCE PHARMA
Incyte Names Richard Hoffman As EVP & General Counsel
01 Dec 2025 //
PHARMIWEB
Incyte To Present At Upcoming Investor Conferences
19 Nov 2025 //
BUSINESSWIRE
Incyte Expands Moments Of Clarity Program For Vitiligo
06 Nov 2025 //
BUSINESS WIRE
Incyte to Present at Upcoming Investor Conferences
30 Oct 2025 //
BUSINESSWIRE
Incyte & Enable Injections Announce Partnership for enFuse System
27 Oct 2025 //
BUSINESS WIRE
Incyte Unveils Ph 3b Opzelura Data In Moderate Atopic Dermatitis
25 Oct 2025 //
BUSINESSWIRE
Incyte To Report Third Quarter Financial Results
08 Oct 2025 //
BUSINESSWIRE
Incyte Issues Inducement Grant Under Nasdaq LR 5635(c)(4)
24 Sep 2025 //
BUSINESSWIRE
Incyte Appoints Dave Gardner as EVP and Chief Strategy Officer
22 Sep 2025 //
BUSINESSWIRE
Incyte Gets FDA OK for Opzelura in Kids with Atopic Dermatitis
18 Sep 2025 //
BUSINESSWIRE
FDA Approves Incyte`s Eczema Cream for Pediatric Patients
18 Sep 2025 //
REUTERS
Incyte to Showcase Dermatology Progress at EADV Congress 2025
10 Sep 2025 //
BUSINESSWIRE
Incyte Unveils HS TRUTHS on Hidradenitis Suppurativa Experience
03 Sep 2025 //
BUSINESSWIRE
Incyte sheds light on life with HS in new HCP campaign
03 Sep 2025 //
FIERCE PHARMA
Incyte Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
27 Aug 2025 //
BUSINESSWIRE
Incyte Taps Soni Basi as EVP and Chief Human Resources Officer
25 Aug 2025 //
CONTRACTPHARMA
Incyte to Present at Upcoming Investor Conferences
19 Aug 2025 //
BUSINESSWIRE
Actuate, Incyte, Pitt to Test Elraglusib in Pancreatic Cancer
06 Aug 2025 //
GLOBENEWSWIRE
Incyte`s CFO Christiana Stamoulis Steps Down
05 Aug 2025 //
BUSINESSWIRE
Incyte`s Q2 2025 Financial Results and Clinical Program Updates
29 Jul 2025 //
BUSINESSWIRE
Incyte to Report Second Quarter Financial Results
10 Jul 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
02 Jul 2025 //
BUSINESSWIRE
Incyte Appoints Bill Meury Chief Executive Officer
26 Jun 2025 //
CONTRACTPHARMA
Incyte Appoints Bill Meury CEO as Hoppenot Retires
26 Jun 2025 //
BUSINESSWIRE
Incyte presents positive data for mutCALR therapy at EHA2025
15 Jun 2025 //
BUSINESSWIRE
Qiagen, Incyte Team Up on MPN Companion Diagnostics
15 Jun 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
06 Jun 2025 //
BUSINESSWIRE
Incyte to Present at Upcoming Investor Conference
27 May 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
07 May 2025 //
BUSINESSWIRE
Incyte, Novartis reach settlement in Jakafi royalty dispute
06 May 2025 //
FIERCE PHARMA
Incyte to Present at Upcoming Investor Conference
01 May 2025 //
BUSINESSWIRE
Incyte predicts low tariff impact, blood cancer drug forecast
29 Apr 2025 //
REUTERS
Incyte Reports 2025 Q1 Financials and Clinical Program Updates
29 Apr 2025 //
BUSINESSWIRE
Incyte to Present Early-Stage Oncology Data at AACR 2025
25 Apr 2025 //
BUSINESSWIRE
Incyte to Present New Oncology Data at 2025 ASCO Annual Meeting
23 Apr 2025 //
BUSINESSWIRE
Sun Pharma beats Incyte in appeals, teeing up US alopecia launch
12 Apr 2025 //
FIERCE PHARMA
Incyte to Report First Quarter Financial Results
10 Apr 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
07 Apr 2025 //
BUSINESSWIRE
Incyte reports positive results from Phase 3 trials of Povorcitinib
17 Mar 2025 //
BUSINESSWIRE
Incyte`s skin disease drug meets main goal in 2 studies
17 Mar 2025 //
REUTERS
Incyte posts mixed Opzelura results in prurigo nodularis
11 Mar 2025 //
FIERCE PHARMA
Incyte Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Mar 2025 //
BUSINESSWIRE
Incyte To Present New Dermatology Data At AAD 2025
28 Feb 2025 //
BUSINESSWIRE
Incyte`s downbeat annual sales of skin disease drug, shares fall
11 Feb 2025 //
REUTERS
Incyte Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Feb 2025 //
BUSINESSWIRE
Incyte to Report Q4 and Year-End 2024 Financial Results
21 Jan 2025 //
BUSINESSWIRE
Incyte Highlight Goals, Growth At J.P. Morgan Healthcare Conference
13 Jan 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Jan 2025 //
BUSINESSWIRE
